Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season

Vaccine

Volumn 33, Issue 1, 2015, Pages 246-251

  Belongia, Edward A ^a   Sundaram, Maria E ^a   McClure, David L ^a   Meece, Jennifer K ^a   Ferdinands, Jill ^b,c   VanWormer, Jeffrey J ^a  

^a MARSHFIELD CLINIC   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Immunity; Influenza; Influenza vaccine; Vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE;

ACUTE RESPIRATORY TRACT DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; EPIDEMIC; FEMALE; HUMAN; IMMUNITY; INFANT; INFLUENZA A (H3N2); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; SEASON; IMMUNOLOGY; INFLUENZA VIRUS A H3N2; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; NASOPHARYNX; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NASOPHARYNX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919420147     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.052     Document Type: Article

References (18)

1. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44.
2. Ohmit S.E., Petrie J.G., Cross R.T., Johnson E., Monto A.S. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011, 204(December (12)):1879-1885.
3. Petrie J.G., Ohmit S.E., Johnson E., Cross R.T., Monto A.S. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011, 203(May (9)):1309-1315.
4. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011;30(December ((12)):1081-5.
5. Skowronski D.M., Tweed S.A., Serres G.D. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant. J Infect Dis 2008, 197:490-502.
6. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Eurosurveillance 2013;18(5):pii=20390.
7. Pebody RG, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Eurosurveillance 2013;18(5):pii=20389.
8. Castilla J, Martínez-Baz I, Martínez-Artola V, Reina G, Pozo F, García Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Eurosurveillance 2013;18(5):pii=20388.
9. Belongia E.A., Kieke B.A., Donahue J.G., Coleman L.A., Irving S.A., Meece J.K., et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine 2011, 29(September (38)):6558-6563.
10. Greenlee R.T. Measuring disease frequency in the Marshfield Epidemiologic Study Area (MESA). Clin Med Res 2003, 1(4):273-280.
11. Irving S.A., Donahue J.G., Shay D.K., Ellis-Coyle T.L., Belongia E.A. Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine 2009, 27(47):6546-6549.
12. Ambrose C.S., Wu X., Belshe R.B. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010, 29(September (9)):806-811.
13. Cao W., Kim J.H., Chirkova T., Reber A.J., Biber R., Shay D.K., et al. Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Rev Vaccines 2011, 10(11):1529-1537.
14. McElhaney J.E. Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines. Aging Health 2008, 4(6):603-613.
15. Murasko D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002, 37(2-3):427-439.
16. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176(10):6333-6339.
17. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. Morbid Mortal Weekly Rep 2012;61(32):613-8.
18. Toback S.L., Herley J., Edelman L., Ambrose C.S. Trends in US pediatric influenza vaccination from 2006 to 2010 among children with private insurance. Vaccine 2011, 29(25):2445-2449.